Dave Singh
#130,200
Most Influential Person Now
Researcher
Dave Singh's AcademicInfluence.com Rankings
Dave Singhengineering Degrees
Engineering
#4433
World Rank
#5626
Historical Rank
Electrical Engineering
#1125
World Rank
#1209
Historical Rank
Dave Singhcomputer-science Degrees
Computer Science
#5686
World Rank
#6004
Historical Rank
Computational Linguistics
#854
World Rank
#867
Historical Rank
Machine Learning
#1603
World Rank
#1625
Historical Rank
Artificial Intelligence
#1837
World Rank
#1869
Historical Rank
Download Badge
Engineering Computer Science
Dave Singh's Degrees
- PhD Computer Science Stanford University
- Masters Electrical Engineering University of California, Berkeley
- Bachelors Computer Engineering University of California, Berkeley
Similar Degrees You Can Earn
Why Is Dave Singh Influential?
(Suggest an Edit or Addition)Dave Singh's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report. GOLD Executive Summary. (2017) (3143)
- Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease: the GOLD science committee report 2019 (2019) (1127)
- Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Lung Disease 2017 Report (2017) (1025)
- Once‐Daily Single‐Inhaler Triple versus Dual Therapy in Patients with COPD (2018) (759)
- The nuclear receptor REV-ERBα mediates circadian regulation of innate immunity through selective regulation of inflammatory cytokines (2011) (502)
- Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial (2018) (437)
- Single inhaler triple therapy versus inhaled corticosteroid plus long-acting β2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial (2016) (371)
- Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary (2017) (360)
- Blood Eosinophils: A Biomarker of Response to Extrafine Beclomethasone/Formoterol in Chronic Obstructive Pulmonary Disease. (2015) (352)
- Eosinophilic inflammation in COPD: prevalence and clinical characteristics (2014) (351)
- Single inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel group, randomised controlled trial (2017) (328)
- Global Initiative for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease. The 2020 GOLD Science Committee Report on COVID-19 and Chronic Obstructive Pulmonary Disease (2020) (257)
- Inhaled corticosteroids and COVID-19: a systematic review and clinical perspective (2020) (240)
- Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial (2020) (231)
- Triple Inhaled Therapy at Two Glucocorticoid Doses in Moderate-to-Very-Severe COPD. (2020) (226)
- The effect of inhaled IFN-β on worsening of asthma symptoms caused by viral infections. A randomized trial. (2014) (219)
- Current concepts in targeting chronic obstructive pulmonary disease pharmacotherapy: making progress towards personalised management (2015) (201)
- Efficacy and safety of twice-daily aclidinium bromide in COPD patients: the ATTAIN study (2012) (190)
- Superiority of “triple” therapy with salmeterol/fluticasone propionate and tiotropium bromide versus individual components in moderate to severe COPD (2008) (177)
- Non-invasive phenotyping using exhaled volatile organic compounds in asthma (2011) (176)
- Efficacy and safety of aclidinium bromide/formoterol fumarate fixed-dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM-COPD): a multicentre, randomised study (2014) (175)
- Sputum neutrophils as a biomarker in COPD: findings from the ECLIPSE study (2010) (166)
- Tiotropium + olodaterol shows clinically meaningful improvements in quality of life. (2015) (153)
- Inhaled corticosteroids in COPD: friend or foe? (2018) (145)
- CD4-regulatory cells in COPD patients. (2007) (145)
- Benralizumab for the Prevention of COPD Exacerbations. (2019) (138)
- Once-daily NVA237 improves exercise tolerance from the first dose in patients with COPD: the GLOW3 trial (2012) (134)
- Selective inducible nitric oxide synthase inhibition has no effect on allergen challenge in asthma. (2007) (134)
- Blood eosinophils and treatment response with triple and dual combination therapy in chronic obstructive pulmonary disease: analysis of the IMPACT trial. (2019) (131)
- MUC5B is the major mucin in the gel phase of sputum in chronic obstructive pulmonary disease. (2008) (126)
- Exhaled breath condensate biomarkers in COPD (2008) (124)
- Efficacy and safety of RPL554, a dual PDE3 and PDE4 inhibitor, in healthy volunteers and in patients with asthma or chronic obstructive pulmonary disease: findings from four clinical trials. (2013) (122)
- Aclidinium bromide and formoterol fumarate as a fixed-dose combination in COPD: pooled analysis of symptoms and exacerbations from two six-month, multicentre, randomised studies (ACLIFORM and AUGMENT) (2015) (117)
- Non-invasive metabolomic analysis of breath using differential mobility spectrometry in patients with chronic obstructive pulmonary disease and healthy smokers. (2010) (112)
- LABA/LAMA combinations versus LAMA monotherapy or LABA/ICS in COPD: a systematic review and meta-analysis (2017) (109)
- Reproducibility of exhaled breath condensate pH in chronic obstructive pulmonary disease (2005) (109)
- Blood and sputum eosinophils in COPD; relationship with bacterial load (2017) (109)
- The pathology of small airways disease in COPD: historical aspects and future directions (2019) (107)
- Identification of cells expressing IL-17A and IL-17F in the lungs of patients with COPD. (2011) (107)
- Electronic cigarette exposure triggers neutrophil inflammatory responses (2016) (107)
- Measuring bronchodilation in COPD clinical trials. (2005) (104)
- Extrafine beclomethasone/formoterol in severe COPD patients with history of exacerbations. (2014) (103)
- Exploring the relevance and extent of small airways dysfunction in asthma (ATLANTIS): baseline data from a prospective cohort study. (2019) (101)
- Single inhaler extrafine triple therapy in uncontrolled asthma (TRIMARAN and TRIGGER): two double-blind, parallel-group, randomised, controlled phase 3 trials (2019) (100)
- Biomarkers of systemic inflammation and depression and fatigue in moderate clinically stable COPD (2011) (100)
- Impulse oscillometry in COPD: identification of measurements related to airway obstruction, airway conductance and lung volumes. (2009) (99)
- A Randomized, Placebo‐Controlled Study of the Effects of the p38 MAPK Inhibitor SB‐681323 on Blood Biomarkers of Inflammation in COPD Patients (2010) (99)
- The prevalence of small airways disease in adult asthma: A systematic literature review. (2016) (98)
- alpha,beta-Unsaturated aldehydes contained in cigarette smoke elicit IL-8 release in pulmonary cells through mitogen-activated protein kinases. (2009) (97)
- Increased phosphorylated p38 mitogen-activated protein kinase in COPD lungs (2012) (96)
- Inhibition of the asthmatic allergen challenge response by the CRTH2 antagonist OC000459 (2012) (93)
- Efficacy and safety of tiotropium Respimat® SMI in COPD in two 1-year randomized studies (2010) (93)
- Effect of tralokinumab, an interleukin-13 neutralising monoclonal antibody, on eosinophilic airway inflammation in uncontrolled moderate-to-severe asthma (MESOS): a multicentre, double-blind, randomised, placebo-controlled phase 2 trial. (2018) (90)
- Depression and its relationship with poor exercise capacity, BODE index and muscle wasting in COPD. (2009) (89)
- The effect of peroxisome proliferator-activated receptor-&ggr; ligands on in vitro and in vivo models of COPD (2013) (88)
- Goals of COPD treatment: Focus on symptoms and exacerbations. (2020) (87)
- The inhaled phosphodiesterase 4 inhibitor GSK256066 reduces allergen challenge responses in asthma (2010) (85)
- Sputum microbiome temporal variability and dysbiosis in chronic obstructive pulmonary disease exacerbations: an analysis of the COPDMAP study (2017) (84)
- Exhaled volatile organic compounds for phenotyping chronic obstructive pulmonary disease: a cross-sectional study (2012) (82)
- Reduction in All-Cause Mortality with Fluticasone Furoate/Umeclidinium/Vilanterol in Patients with Chronic Obstructive Pulmonary Disease (2020) (82)
- Neutrophil Chemotaxis Caused by Chronic Obstructive Pulmonary Disease Alveolar Macrophages: The Role of CXCL8 and the Receptors CXCR1/CXCR2 (2013) (81)
- Nebulised heparin as a treatment for COVID-19: scientific rationale and a call for randomised evidence (2020) (81)
- Genetics of Sputum Gene Expression in Chronic Obstructive Pulmonary Disease (2011) (80)
- Cigarette smoke and its component acrolein augment IL-8/CXCL8 mRNA stability via p38 MAPK/MK2 signaling in human pulmonary cells. (2012) (79)
- A phase 1 study evaluating the pharmacokinetics, safety and tolerability of repeat dosing with a human IL-13 antibody (CAT-354) in subjects with asthma (2010) (79)
- Characterisation of lung macrophage subpopulations in COPD patients and controls (2017) (78)
- Chronic Obstructive Pulmonary Disease Biomarkers and Their Interpretation. (2019) (77)
- Airway host-microbiome interactions in chronic obstructive pulmonary disease (2019) (75)
- The use of plethysmography and oscillometry to compare long-acting bronchodilators in patients with COPD. (2008) (74)
- Increased airway T regulatory cells in asthmatic subjects. (2010) (74)
- Predictors of objective cough frequency in chronic obstructive pulmonary disease. (2013) (73)
- Induced sputum genes associated with spirometric and radiological disease severity in COPD ex-smokers (2011) (71)
- A comparison of exhaled nitric oxide measurements performed using three different analysers. (2006) (70)
- Current Controversies in the Pharmacological Treatment of Chronic Obstructive Pulmonary Disease. (2016) (70)
- Pulmonary inflammation in patients with chronic obstructive pulmonary disease with higher blood eosinophil counts. (2017) (70)
- Reduced All-Cause Mortality in the ETHOS Trial of Budesonide/Glycopyrrolate/Formoterol for Chronic Obstructive Pulmonary Disease. A Randomized, Double-Blind, Multicenter, Parallel-Group Study (2020) (69)
- Characterisation and impact of reported and unreported exacerbations: results from ATTAIN (2014) (69)
- Identification of lipocalin and apolipoprotein A1 as biomarkers of chronic obstructive pulmonary disease. (2010) (69)
- Cigarette smoke extract induced cytokine and chemokine gene expression changes in COPD macrophages. (2008) (68)
- Unfractionated heparin inhibits live wild type SARS‐CoV‐2 cell infectivity at therapeutically relevant concentrations (2020) (68)
- COVID-19 and COPD: a narrative review of the basic science and clinical outcomes (2020) (67)
- Azithromycin for Acute Exacerbations of Asthma : The AZALEA Randomized Clinical Trial. (2016) (65)
- Impaired Mitochondrial Microbicidal Responses in Chronic Obstructive Pulmonary Disease Macrophages (2017) (65)
- Influence of lung CT changes in chronic obstructive pulmonary disease (COPD) on the human lung microbiome (2017) (65)
- A comparison of lung function methods for assessing dose-response effects of salbutamol. (2004) (64)
- Exploring the relevance and extent of small airways dysfunction in asthma: baseline data from the AssessmenT of smalL Airways involvemeNT In aSthma (ATLANTIS) prospective cohort study (2019) (64)
- Increased ACE2 Expression in Bronchial Epithelium of COPD Patients who are Overweight (2020) (62)
- New combination bronchodilators for chronic obstructive pulmonary disease: current evidence and future perspectives Dave Singh (2015) (62)
- Identification and functional analysis of SKA2 interaction with the glucocorticoid receptor (2008) (61)
- Inhaled corticosteroid containing combinations and mortality in COPD (2018) (61)
- Umeclidinium/vilanterol versus fluticasone propionate/salmeterol in COPD: a randomised trial (2015) (60)
- COPD phenotype description using principal components analysis (2009) (59)
- Activin Type II Receptor Blockade for Treatment of Muscle Depletion in Chronic Obstructive Pulmonary Disease. A Randomized Trial (2019) (59)
- Prevention of clinically important deteriorations in COPD with umeclidinium/vilanterol (2016) (58)
- Budesonide/formoterol vs. salmeterol/fluticasone in COPD: a systematic review and adjusted indirect comparison of pneumonia in randomised controlled trials (2011) (58)
- Predicting response to benralizumab in chronic obstructive pulmonary disease: analyses of GALATHEA and TERRANOVA studies. (2020) (57)
- Altered Gene Expression in Blood and Sputum in COPD Frequent Exacerbators in the ECLIPSE Cohort (2014) (57)
- Safety of indacaterol in the treatment of patients with COPD (2011) (57)
- The reproducibility of COPD blood eosinophil counts (2018) (56)
- Magnitude of umeclidinium/vilanterol lung function effect depends on monotherapy responses: Results from two randomised controlled trials. (2016) (56)
- Pharmacological strategies to reduce exacerbation risk in COPD: a narrative review (2016) (55)
- The effect of electronic cigarette and tobacco smoke exposure on COPD bronchial epithelial cell inflammatory responses (2018) (55)
- A comparison of plethysmography, spirometry and oscillometry for assessing the pulmonary effects of inhaled ipratropium bromide in healthy subjects and patients with asthma. (2005) (53)
- The repeatability of interleukin-6, tumor necrosis factor-α, and C-reactive protein in COPD patients over one year (2009) (53)
- Identification of airway mucosal type 2 inflammation by using clinical biomarkers in asthmatic patients (2017) (53)
- Phase 2, randomised placebo-controlled trial to evaluate the efficacy and safety of an anti-GM-CSF antibody (KB003) in patients with inadequately controlled asthma (2016) (53)
- ACCORD: A Multicentre, Seamless, Phase 2 Adaptive Randomisation Platform Study to Assess the Efficacy and Safety of Multiple Candidate Agents for the Treatment of COVID-19 in Hospitalised Patients: A structured summary of a study protocol for a randomised controlled trial (2020) (51)
- Inflammatory Endotype–associated Airway Microbiome in Chronic Obstructive Pulmonary Disease Clinical Stability and Exacerbations: A Multicohort Longitudinal Analysis (2020) (51)
- Inhibition of Lipopolysaccharide-Stimulated Chronic Obstructive Pulmonary Disease Macrophage Inflammatory Gene Expression by Dexamethasone and the p38 Mitogen-Activated Protein Kinase Inhibitor N-cyano-N′-(2-{[8-(2,6-difluorophenyl)-4-(4-fluoro-2-methylphenyl)-7-oxo-7,8-dihydropyrido[2,3-d] pyrimidi (2009) (51)
- Use of different exhaled nitric oxide multiple flow rate models in COPD (2007) (50)
- Loss of Glucocorticoid Receptor Expression by DNA Methylation Prevents Glucocorticoid Induced Apoptosis in Human Small Cell Lung Cancer Cells (2011) (49)
- Increased levels of soluble interleukin-6 receptor and CCL3 in COPD sputum (2014) (48)
- Effects of tiotropium + olodaterol versus tiotropium or placebo by COPD disease severity and previous treatment history in the OTEMTO® studies (2016) (47)
- Differential Effects of p38, MAPK, PI3K or Rho Kinase Inhibitors on Bacterial Phagocytosis and Efferocytosis by Macrophages in COPD (2016) (46)
- Genetic control of gene expression at novel and established chronic obstructive pulmonary disease loci. (2015) (46)
- Asthma characteristics and biomarkers from the Airways Disease Endotyping for Personalized Therapeutics (ADEPT) longitudinal profiling study (2015) (45)
- Opsonic Phagocytosis in Chronic Obstructive Pulmonary Disease Is Enhanced by Nrf2 Agonists (2018) (45)
- Development, dimensions, reliability and validity of the novel Manchester COPD fatigue scale (2009) (45)
- Perception of symptoms and quality of life – comparison of patients’ and physicians’ views in the COPD MIRROR study (2017) (44)
- Non-invasive biomarkers and pulmonary function in smokers (2008) (43)
- CRTH2 antagonists in asthma: current perspectives (2017) (42)
- Reduced glucocorticoid receptor expression and function in airway neutrophils. (2012) (41)
- Emphysema- and airway-dominant COPD phenotypes defined by standardised quantitative computed tomography (2016) (41)
- Blood Eosinophil Counts in Clinical Trials for Chronic Obstructive Pulmonary Disease (2020) (40)
- A randomised, placebo- and active-controlled dose-finding study of aclidinium bromide administered twice a day in COPD patients. (2012) (40)
- Assessing Short-term Deterioration in Maintenance-naïve Patients with COPD Receiving Umeclidinium/Vilanterol and Tiotropium: A Pooled Analysis of Three Randomized Trials (2016) (40)
- The sputum microbiome is distinct between COPD and health, independent of smoking history (2020) (38)
- Triple therapy in COPD: new evidence with the extrafine fixed combination of beclomethasone dipropionate, formoterol fumarate, and glycopyrronium bromide (2017) (38)
- Time of Day Affects Eosinophil Biomarkers in Asthma: Implications for Diagnosis and Treatment (2018) (37)
- Longitudinal stability of asthma characteristics and biomarkers from the Airways Disease Endotyping for Personalized Therapeutics (ADEPT) study (2016) (37)
- The effects of corticosteroids on COPD lung macrophages: a pooled analysis (2015) (36)
- Extrafine Beclomethasone/formoterol compared to Fluticasone/salmeterol Combination Therapy in COPD (2014) (36)
- Toll‐like receptor 3 blockade in rhinovirus‐induced experimental asthma exacerbations: A randomized controlled study (2017) (36)
- A novel inhaled phosphodiesterase 4 inhibitor (CHF6001) reduces the allergen challenge response in asthmatic patients. (2016) (35)
- Effect of the inhaled PDE4 inhibitor CHF6001 on biomarkers of inflammation in COPD (2019) (35)
- Reduction in clinically important deterioration in chronic obstructive pulmonary disease with aclidinium/formoterol (2017) (34)
- Inhaled LPS challenges in smokers: a study of pulmonary and systemic effects. (2012) (33)
- RV568, a narrow-spectrum kinase inhibitor with p38 MAPK-α and -γ selectivity, suppresses COPD inflammation (2017) (33)
- Clinical characteristics and airway inflammation profile of COPD persistent sputum producers. (2014) (33)
- Down Regulation of T Cell Receptor Expression in COPD Pulmonary CD8 Cells (2013) (33)
- Oral and inhaled p38 MAPK inhibitors: effects on inhaled LPS challenge in healthy subjects (2015) (33)
- A trial of beclomethasone/formoterol in COPD using EXACT-PRO to measure exacerbations (2012) (32)
- The short-term bronchodilator effects of the dual phosphodiesterase 3 and 4 inhibitor RPL554 in COPD (2018) (32)
- T lymphocyte insensitivity to corticosteroids in chronic obstructive pulmonary disease (2012) (32)
- Pharmacodynamics, pharmacokinetics and safety of revefenacin (TD-4208), a long-acting muscarinic antagonist, in patients with chronic obstructive pulmonary disease (COPD): Results of two randomized, double-blind, phase 2 studies. (2018) (32)
- Feasibility assessment of using oxygen-enhanced magnetic resonance imaging for evaluating the effect of pharmacological treatment in COPD. (2014) (32)
- Bacteria and sputum inflammatory cell counts; a COPD cohort analysis (2020) (31)
- Circadian rhythm of exhaled biomarkers in health and asthma (2019) (30)
- The EvA study: aims and strategy (2012) (30)
- Anti-inflammatory potential of PI3Kδ and JAK inhibitors in asthma patients (2016) (30)
- The role of the liver X receptor in chronic obstructive pulmonary disease (2013) (29)
- LPS challenge in healthy subjects: an investigation of neutrophil chemotaxis mechanisms involving CXCR1 and CXCR2. (2012) (29)
- The Effect of Fatigue and Fatigue Intensity on Exercise Tolerance in Moderate COPD (2016) (29)
- Mechanisms of corticosteroid insensitivity in COPD alveolar macrophages exposed to NTHi (2017) (28)
- Attached stratified mucus separates bacteria from the epithelial cells in COPD lungs. (2018) (28)
- Effect of 12 weeks of once-daily tiotropium/olodaterol on exercise endurance during constant work-rate cycling and endurance shuttle walking in chronic obstructive pulmonary disease (2018) (28)
- Efficacy and safety of nebulized glycopyrrolate for administration using a high efficiency nebulizer in patients with chronic obstructive pulmonary disease (2014) (28)
- Risankizumab in Severe Asthma - A Phase 2a, Placebo-Controlled Trial. (2021) (28)
- A phase 2 multiple ascending dose study of the inhaled pan-JAK inhibitor nezulcitinib (TD-0903) in severe COVID-19 (2021) (27)
- Tuberculin test measurement: variability due to the time of reading. (2002) (27)
- (cid:1) , (cid:2) -Unsaturated aldehydes contained in cigarette smoke elicit IL-8 release in pulmonary cells through mitogen-activated protein kinases (2009) (26)
- Small Airway Disease in Patients with Chronic Obstructive Pulmonary Disease (2017) (26)
- Feasibility and challenges of using multiple breath washout in COPD (2018) (26)
- Reduction in All-Cause Mortality with Fluticasone Furoate/Umeclidinium/Vilanterol in COPD Patients. (2020) (26)
- The effect of gas standardisation on exhaled breath condensate pH (2006) (26)
- Systematic literature review of patient-reported outcome measures used in assessment and measurement of sleep disorders in chronic obstructive pulmonary disease (2015) (25)
- The stability of blood Eosinophils in chronic obstructive pulmonary disease (2020) (25)
- A phase III study of triple therapy with budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler 320/18/9.6 μg and 160/18/9.6 μg using co-suspension delivery technology in moderate-to-very severe COPD: The ETHOS study protocol. (2019) (25)
- CD8 chemokine receptors in chronic obstructive pulmonary disease (2008) (25)
- Clinical characteristics of eosinophilic COPD versus COPD patients with a history of asthma (2017) (25)
- Corticosteroid insensitive alveolar macrophages from asthma patients; synergistic interaction with a p38 mitogen-activated protein kinase (MAPK) inhibitor. (2014) (25)
- Blood eosinophil count and airway epithelial transcriptome relationships in COPD versus asthma (2019) (24)
- Impact factor and its role in academic promotion (2009) (24)
- A dose-ranging study of the inhaled dual phosphodiesterase 3 and 4 inhibitor ensifentrine in COPD (2020) (24)
- P38 MAPK and glucocorticoid receptor crosstalk in bronchial epithelial cells (2020) (23)
- Chronic Obstructive Pulmonary Disease Individualized Therapy: Tailored Approach to Symptom Management (2016) (23)
- Evaluation of Glucocorticoid Receptor Function in COPD Lung Macrophages Using Beclomethasone-17-Monopropionate (2013) (23)
- The effects of repeated Toll-like receptors 2 and 4 stimulation in COPD alveolar macrophages (2018) (23)
- Unmet needs for the assessment of small airways dysfunction in asthma: introduction to the ATLANTIS study (2015) (23)
- Diesel Exhaust Particle Exposure In Vitro Alters Monocyte Differentiation and Function (2012) (23)
- Effect of AeroChamber Plus™ on the lung and systemic bioavailability of beclometasone dipropionate/formoterol pMDI. (2011) (23)
- Comparative effectiveness of triple therapy versus dual bronchodilation in COPD (2019) (23)
- The effects of dexamethasone on cigarette smoke induced gene expression changes in COPD macrophages. (2010) (23)
- Therapeutic index of inhaled corticosteroids in asthma: A dose–response comparison on airway hyperresponsiveness and adrenal axis suppression (2020) (22)
- Characterization of TLR-induced inflammatory responses in COPD and control lung tissue explants (2016) (22)
- Rhinovirus‐16 induced temporal interferon responses in nasal epithelium links with viral clearance and symptoms (2019) (22)
- The modulatory effects of the PDE4 inhibitors CHF6001 and roflumilast in alveolar macrophages and lung tissue from COPD patients. (2019) (22)
- PI3K, p38 and JAK/STAT signalling in bronchial tissue from patients with asthma following allergen challenge (2018) (22)
- Extrafine beclometasone diproprionate/formoterol fumarate: a review of its effects in chronic obstructive pulmonary disease (2016) (22)
- Inhaled corticosteroids and COVID-19-related mortality: confounding or clarifying? (2020) (22)
- Ampicillin resistance in Haemophilus influenzae from COPD patients in the UK (2017) (21)
- Leukotriene B4 levels in sputum from asthma patients (2016) (21)
- Novel anti-inflammatory agents in COPD: targeting lung and systemic inflammation. (2013) (21)
- Blood eosinophils as a biomarker of future COPD exacerbation risk: pooled data from 11 clinical trials (2020) (21)
- Increased type 2 inflammation post rhinovirus infection in patients with moderate asthma. (2020) (21)
- INHALEd nebulised unfractionated HEParin for the treatment of hospitalised patients with COVID‐19 (INHALE‐HEP): Protocol and statistical analysis plan for an investigator‐initiated international metatrial of randomised studies (2020) (21)
- The effects of corticosteroids on cytokine production from asthma lung lymphocytes. (2014) (20)
- Pharmacological treatment of COPD: the devil is always in the detail (2018) (20)
- Do inhaled corticosteroid/long-acting beta2-agonist fixed combinations provide superior clinical benefits compared with separate inhalers? A literature reappraisal. (2012) (20)
- The effect of the novel phosphodiesterase-4 inhibitor MEM 1414 on the allergen induced responses in mild asthma (2014) (20)
- Change in blood eosinophils following treatment with inhaled corticosteroids may predict long-term clinical response in COPD (2020) (20)
- Lung microbiome composition and bronchial epithelial gene expression in patients with COPD versus healthy individuals: a bacterial 16S rRNA gene sequencing and host transcriptomic analysis. (2021) (20)
- Type 2 inflammation in eosinophilic chronic obstructive pulmonary disease (2020) (20)
- When to use single-inhaler triple therapy in COPD: a practical approach for primary care health care professionals (2019) (20)
- Corticosteroid effects on COPD alveolar macrophages: Dependency on cell culture methodology (2014) (20)
- Comparison of the effects of salmeterol/fluticasone propionate with fluticasone propionate on airway physiology in adults with mild persistent asthma (2007) (20)
- Multi-omics links IL-6 trans-signalling with neutrophil extracellular trap formation and Haemophilus infection in COPD (2021) (19)
- Randomized controlled trials and real-world observational studies in evaluating cardiovascular safety of inhaled bronchodilator therapy in COPD (2016) (19)
- Predicting Corticosteroid Response in Chronic Obstructive Pulmonary Disease. Blood Eosinophils Gain Momentum. (2017) (19)
- Plethysmography and impulse oscillometry assessment of tiotropium and ipratropium bromide; a randomized, double-blind, placebo-controlled, cross-over study in healthy subjects. (2006) (19)
- Additive anti-inflammatory effects of corticosteroids and phosphodiesterase-4 inhibitors in COPD CD8 cells (2016) (19)
- P38 inhibition in COPD; cautious optimism (2013) (19)
- Extrafine triple therapy delays COPD clinically important deterioration vs ICS/LABA, LAMA, or LABA/LAMA (2019) (19)
- Erratum to "Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary" [Arch Bronconeumol. 2017;53:128-49]. (2017) (19)
- A Disintegrin and A Metalloproteinase Domain-8 (ADAM8): A Novel Protective Proteinase in COPD (2018) (19)
- COPD monocytes demonstrate impaired migratory ability (2017) (18)
- The bronchodilator effects of extrafine glycopyrronium added to combination treatment with beclometasone dipropionate plus formoterol in COPD: A randomised crossover study (the TRIDENT study). (2016) (18)
- Characteristics and longitudinal progression of chronic obstructive pulmonary disease in GOLD B patients (2017) (18)
- The Effect of Inhaled Corticosteroid Withdrawal and Baseline Inhaled Treatment on Exacerbations in the IMPACT Study. A Randomized, Double-Blind, Multicenter Clinical Trial (2020) (18)
- Sputum and blood transcriptomics characterisation of the inhaled PDE4 inhibitor CHF6001 on top of triple therapy in patients with chronic bronchitis (2020) (17)
- Joint statement for the diagnosis, management, and prevention of chronic obstructive pulmonary disease for Gulf Cooperation Council countries and Middle East–North Africa region, 2017 (2017) (17)
- Effects of 12 weeks of once-daily tiotropium and olodaterol fixed-dose combination on exercise endurance in patients with COPD (2014) (17)
- MR Quantitative Equilibrium Signal Mapping: A Reliable Alternative to CT in the Assessment of Emphysema in Patients with Chronic Obstructive Pulmonary Disease. (2015) (17)
- Tolerability of high cumulative doses of the HFA modulite beclomethasone dipropionate/formoterol combination inhaler in asthmatic patients. (2008) (17)
- The effects of smoking on the lipopolysaccharide response and glucocorticoid sensitivity of alveolar macrophages of patients with asthma. (2009) (17)
- Once-daily NVA 237 improves exercise tolerance from the first dose in patients with COPD : the GLOW 3 trial (2012) (17)
- Differential anti-inflammatory effects of budesonide and a p38 MAPK inhibitor AZD7624 on COPD pulmonary cells (2018) (17)
- Biomarkers of collagen turnover are related to annual change in FEV1 in patients with chronic obstructive pulmonary disease within the ECLIPSE study (2017) (17)
- Asthma control and COPD symptom burden in patients using fixed-dose combination inhalers (SPRINT study) (2020) (16)
- Treatment response to indacaterol/glycopyrronium versus salmeterol/fluticasone in exacerbating COPD patients by gender: a post-hoc analysis in the FLAME study (2019) (16)
- The effect of exacerbation history on outcomes in the IMPACT trial (2020) (16)
- Efficacy of Tiotropium/Olodaterol Compared with Tiotropium as a First-Line Maintenance Treatment in Patients with COPD Who Are Naïve to LAMA, LABA and ICS: Pooled Analysis of Four Clinical Trials (2020) (16)
- Gene expression changes caused by the p38 MAPK inhibitor dilmapimod in COPD patients: analysis of blood and sputum samples from a randomized, placebo-controlled clinical trial (2014) (16)
- Effects of Corticosteroids on COPD Lung Macrophage Phenotype and Function. (2020) (16)
- Characterization of the inflammatory response to inhaled lipopolysaccharide in mild to moderate chronic obstructive pulmonary disease. (2015) (16)
- Anti‐inflammatory effects of the phosphodiesterase type 4 inhibitor CHF6001 on bronchoalveolar lavage lymphocytes from asthma patients (2019) (16)
- Neutral sphingomyelinase-2, acid sphingomyelinase, and ceramide levels in COPD patients compared to controls (2016) (15)
- Clinical characteristics of COPD patients with tidal expiratory flow limitation (2017) (15)
- An Evaluation Of Single And Dual Long-Acting Bronchodilator Therapy As Effective Interventions In Maintenance Therapy-Naïve Patients With COPD (2019) (15)
- The role of small airway dysfunction in asthma control and exacerbations: a longitudinal, observational analysis using data from the ATLANTIS study. (2022) (15)
- Reduced risk of clinically important deteriorations by ICS in COPD is eosinophil dependent: a pooled post-hoc analysis (2020) (15)
- Treatment Trials in Pre-COPD and Young COPD: Time to Move Forward. (2021) (15)
- Effects of the Toll-like receptor 7 (TLR7) agonist, AZD8848, on allergen-induced responses in patients with mild asthma: a double-blind, randomised, parallel-group study (2019) (15)
- A Disintegrin and Metalloproteinase Domain‐9: A Novel Proteinase Culprit with Multifarious Contributions to Chronic Obstructive Pulmonary Disease (2018) (15)
- Measuring disease activity in COPD: is clinically important deterioration the answer? (2020) (14)
- Blood eosinophil counts in COPD patients compared to controls (2019) (14)
- P250 Effects Of 12 Weeks Of Once-daily Tiotropium And Olodaterol Fixed-dose Combination On Exercise Endurance In Patients With Copd (2014) (14)
- Weighing the evidence for pharmacological treatment interventions in mild COPD; a narrative perspective (2019) (14)
- Biologics for Chronic Obstructive Pulmonary Disease: Present and Future (2018) (13)
- Inhibition of the early asthmatic response to inhaled allergen by the 5-lipoxygenase activating protein inhibitor GSK2190915: a dose–response study (2013) (13)
- Blood Eosinophil Counts in Chronic Obstructive Pulmonary Disease: A Biomarker of Inhaled Corticosteroid Effects (2020) (13)
- A phase 1/1b study of PUR1900, an inhaled formulation of itraconazole, in healthy volunteers and asthmatics to study safety, tolerability and pharmacokinetics (2019) (13)
- Small airway disease in chronic obstructive pulmonary disease: insights and implications for the clinician. (2020) (13)
- Inhaled long-acting muscarinic antagonists in asthma - A narrative review. (2021) (13)
- The development and first validation of the Manchester Early Morning Symptoms Index (MEMSI) for patients with COPD (2015) (13)
- CRAC channel inhibition produces greater anti-inflammatory effects than glucocorticoids in CD8 cells from COPD patients. (2014) (13)
- Current Controversies in Chronic Obstructive Pulmonary Disease. A Report from the Global Initiative for Chronic Obstructive Lung Disease Scientific Committee (2019) (12)
- Extrafine triple therapy in patients with asthma and persistent airflow limitation (2020) (12)
- Reduced exhaled breath condensate pH in asthmatic smokers using inhaled corticosteroids (2009) (12)
- A Comparison of the Clinical and Induced Sputum Characteristics of Early- and Late-Onset Asthma (2012) (12)
- A dose-ranging study of the bronchodilator effects of abediterol (LAS100977), a long-acting β2-adrenergic agonist, in asthma; a Phase II, randomized study (2014) (12)
- Stability of eosinophilic inflammation in COPD bronchial biopsies (2020) (12)
- COPD sputum eosinophils: relationship to blood eosinophils and the effect of inhaled PDE4 inhibition (2020) (11)
- A phase 2 study to evaluate the safety, efficacy and pharmacokinetics of DP2 antagonist GB001 and to explore biomarkers of airway inflammation in mild‐to‐moderate asthma (2019) (11)
- Resistome analyses of sputum from COPD and healthy subjects reveals bacterial load-related prevalence of target genes (2019) (11)
- Letter to the editor: indacaterol/glycopyrronium/mometasone furoate compared with salmeterol/fluticasone propionate in patients with asthma: a randomized controlled cross-over study (2020) (11)
- Repeatability of induced sputum measurements in moderate to severe asthma. (2014) (11)
- Airway Bacteria Quantification Using Polymerase Chain Reaction Combined with Neutrophil and Eosinophil Counts Identifies Distinct COPD Endotypes (2021) (11)
- Efficacy and safety of CHF6001, a novel inhaled PDE4 inhibitor in COPD: the PIONEER study (2020) (11)
- Impact of Body Mass Index Change on the Prognosis of Chronic Obstructive Pulmonary Disease (2020) (10)
- Determinants of response to inhaled extrafine triple therapy in asthma: analyses of TRIMARAN and TRIGGER (2020) (10)
- High frequency of infection of lung cancer patients with the parasite Toxoplasma gondii (2019) (10)
- Extrafine triple therapy in patients with symptomatic COPD and history of one moderate exacerbation (2019) (10)
- A Randomized Trial of Dual-Acting Bronchodilator AZD8871 for Chronic Obstructive Pulmonary Disease. (2019) (10)
- Tiotropium/Olodaterol Decreases Exacerbation Rates Compared with Tiotropium in a Range of Patients with COPD: Pooled Analysis of the TONADO®/DYNAGITO® Trials (2020) (10)
- Phase I study in healthy participants to evaluate safety, tolerability, and pharmacokinetics of inhaled nezulcitinib, a potential treatment for COVID‐19 (2021) (10)
- An investigation of the anti‐inflammatory effects and a potential biomarker of PI3Kδ inhibition in COPD T cells (2017) (9)
- Tiotropium/Olodaterol Delays Clinically Important Deterioration Compared with Tiotropium Monotherapy in Patients with Early COPD: a Post Hoc Analysis of the TONADO® Trials (2020) (9)
- Bronchodilator efficacy of extrafine glycopyrronium bromide: the Glyco 2 study (2017) (9)
- Outcomes Evaluated in Controlled Clinical Trials on the Management of COVID-19: A Methodological Systematic Review (2020) (9)
- Effects of baseline symptom burden on treatment response in COPD (2019) (9)
- ADAM15 expression is increased in lung CD8+ T cells, macrophages, and bronchial epithelial cells in patients with COPD and is inversely related to airflow obstruction (2020) (9)
- Relief of methacholine-induced bronchospasm with extrafine beclomethasone dipropionate/formoterol in comparison with salbutamol in asthma. (2012) (9)
- Blood eosinophil counts and the development of obstructive lung disease: the Kangbuk Samsung Health Study (2021) (9)
- The novel inhaled glucocorticoid receptor agonist GW870086X protects against adenosine-induced bronchoconstriction in asthma. (2015) (9)
- New Versus Old: The Impact of Changing Patterns of Inhaled Corticosteroid Prescribing and Dosing Regimens in Asthma Management (2022) (9)
- Seretide withdrawal increases airway inflammation in moderate COPD patients (2009) (9)
- Single inhaler triple therapy (SITT) in asthma: Systematic review and practice implications (2021) (9)
- Red Blood Cell-Derived Iron Alters Macrophage Function in COPD (2021) (9)
- Tanimilast, A Novel Inhaled Pde4 Inhibitor for the Treatment of Asthma and Chronic Obstructive Pulmonary Disease (2021) (8)
- Current developments and future directions in COPD (2020) (8)
- Evaluation of the Efficacy and Safety of Two Doses of Aclidinium and Formoterol in Fixed-Dose Combination in Patients With COPD: The ACLIFORM Study (2014) (8)
- Composite endpoints in COPD: clinically important deterioration in the UPLIFT trial (2020) (8)
- Long-Acting Bronchodilators for Chronic Obstructive Pulmonary Disease: Which One(S), How, and When? (2020) (8)
- Improvements in lung function with budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler versus dual therapies in patients with COPD: a sub-study of the ETHOS trial (2021) (8)
- A Disintegrin and Metalloproteinase Domain‐8: A Novel Protective Proteinase in Chronic Obstructive Pulmonary Disease (2018) (8)
- Navafenterol (AZD8871) in patients with COPD: a randomized, double-blind, phase I study evaluating safety and pharmacodynamics of single doses of this novel, inhaled, long-acting, dual-pharmacology bronchodilator (2020) (8)
- Bronchodilator effects, pharmacokinetics and safety of PSX1002-GB, a novel glycopyrronium bromide formulation, in COPD patients; a randomised crossover study. (2016) (8)
- The pharmacokinetics, pharmacodynamics and tolerability of PUR0200, a novel tiotropium formulation, in chronic obstructive pulmonary disease (2018) (8)
- The relationship between airway immunoglobulin activity and eosinophils in COPD (2020) (8)
- Budesonide administered using chlorofluorocarbon and hydrofluoroalkane pressurized metered-dose inhalers: pharmacokinetics, pharmacodynamics and clinical equivalence. (2007) (8)
- Pharmacological treatment of stable chronic obstructive pulmonary disease (2021) (8)
- Blood Eosinophils and Chronic Obstructive Pulmonary Disease: A GOLD Science Committee 2022 Review. (2022) (7)
- The systemic exposure to inhaled beclometasone/formoterol pMDI with valved holding chamber is independent of age and body size. (2015) (7)
- The reproducibility of adenosine monophosphate bronchial challenges in mild, steroid-naive asthmatics. (2008) (7)
- Symptom Improvement Following Treatment with the Inhaled Dual Phosphodiesterase 3 and 4 Inhibitor Ensifentrine in Patients with Moderate to Severe COPD – A Detailed Analysis (2020) (7)
- Eosinophil-derived neurotoxin: A biologically and analytically attractive asthma biomarker. (2021) (7)
- Efficacy and safety of nebulized glycopyrrolate (EP-101) for administration using high efficiency nebulizer in patients with COPD (2011) (7)
- COPD patients with chronic bronchitis and higher sputum eosinophil counts show increased type‐2 and PDE4 gene expression in sputum (2020) (7)
- Chronic Obstructive Pulmonary Disease, Neutrophils and Bacterial Infection: A Complex Web Involving IL-17 and IL-22 Unravels (2015) (7)
- Benefits of Tiotropium/Olodaterol Compared with Tiotropium in Patients with COPD Receiving only LAMA at Baseline: Pooled Analysis of the TONADO® and OTEMTO® Studies (2020) (7)
- Critical assessment of the value of sputum neutrophils (2013) (7)
- Bronchodilator reversibility in patients with COPD revisited: short-term reproducibility (2016) (7)
- CONQUEST Quality Standards: For the Collaboration on Quality Improvement Initiative for Achieving Excellence in Standards of COPD Care (2021) (7)
- Erratum to: Chronic Obstructive Pulmonary Disease Individualized Therapy: Tailored Approach to Symptom Management (2017) (7)
- Systemic exposure to inhaled beclometasone/formoterol DPI is age and body size dependent. (2014) (7)
- The novel bronchodilator navafenterol: a phase 2a, multicentre, randomised, double-blind, placebo-controlled crossover trial in COPD (2021) (6)
- Now We Know Who You Are: A Clear Description of Mononuclear Phagocyte Subsets in the Human Lung. (2016) (6)
- Remote FEV1 Monitoring in Asthma Patients: A Pilot Study (2020) (6)
- Pharmacological treatment for COPD; GOLD 2017 changes direction (2017) (6)
- Dexamethasone and p38 MAPK inhibition of cytokine production from human lung fibroblasts (2020) (6)
- InforMing the PAthway of COPD Treatment (IMPACT) trial: fibrinogen levels predict risk of moderate or severe exacerbations (2021) (6)
- Blood eosinophil counts and treatment response in COPD: analyses of IMPACT (2018) (6)
- Inhibition of LPS Stimulated COPD Macrophage Inflammatory Gene Expression by Dexamethasone and the p38 MAPK Inhibitor SB706504 (2008) (6)
- Single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol and umeclidinium/vilanterol in patients with COPD: results on cardiovascular safety from the IMPACT trial (2020) (6)
- Daily variation in lung function in COPD patients with combined albuterol and ipratropium: results from a 4-week, randomized, crossover study. (2015) (6)
- Effects of the novel toll-like receptor 7 (TLR7) agonist AZD8848 on allergen-induced responses in patients with mild asthma (2012) (6)
- Influenza infection in COPD (2007) (5)
- DuoResp® Spiromax® adherence, satisfaction and ease of use: findings from a multi-country observational study in patients with asthma and COPD in Europe (SPRINT) (2019) (5)
- Higher COPD Assessment Test Score Associated With Greater Exacerbations Risk: A Post Hoc Analysis of the IMPACT Trial. (2021) (5)
- Future concepts in bronchodilation for COPD: dual- versus monotherapy (2021) (5)
- Extrafine triple therapy reduces exacerbations in GOLD B COPD patients: post-hoc analysis of TRILOGY and TRINITY (2017) (5)
- Aclidinium bromide in fixed-dose combination with formoterol fumarate in the management of COPD: an update on the evidence base (2019) (5)
- Gender specific airway gene expression in COPD sub-phenotypes supports a role of mitochondria and of different types of leukocytes (2021) (5)
- Pharmacology Versus Convenience: A Benefit/Risk Analysis of Regular Maintenance Versus Infrequent or As-Needed Inhaled Corticosteroid Use in Mild Asthma (2021) (5)
- Management of Chronic Obstructive Pulmonary Disease: A Personalized Interpretation of the Global Initiative for Chronic Obstructive Lung Disease (GOLD) - ABCD Recommendations (2016) (5)
- Efficacy of aclidinium/formoterol 400/12 µg, analyzed by airflow obstruction severity, age, sex, and exacerbation history: pooled analysis of ACLIFORM and AUGMENT (2019) (5)
- Single-Inhaler Triple Therapy and Health-Related Quality of Life in COPD: The IMPACT Study (2020) (5)
- The effect of the inhaled PDE4 inhibitor CHF6001 on allergen-induced inflammation in asthmatics (2014) (5)
- Research highlights from the 2018 European Respiratory Society International Congress: airway disease (2019) (5)
- Evaluation of New Drugs for Asthma and COPD: Endpoints, Biomarkers and Clinical Trial Design. (2016) (5)
- P189 Reduced COPD Exacerbations Associated with Aclidinium Bromide Versus Placebo: A Pooled Analysis of Phase III Data (2012) (5)
- Acute cardiovascular safety of two formulations of beclometasone dipropionate/formoterol fumarate in COPD patients: A single-dose, randomised, placebo-controlled crossover study. (2017) (5)
- Safety, pharmacokinetic and pharmacodynamic profile of RV568, a narrow spectrum kinase inhibitor, following repeat inhaled dosing in COPD patients (2013) (5)
- Novel anti-inflammatory treatments for asthma (2008) (5)
- Triple Versus Dual Combination Therapy in Chronic Obstructive Pulmonary Disease in Asian Countries: Analysis of the IMPACT Trial (2020) (5)
- A Phase 1 study of the long‐acting anti‐IL‐5 monoclonal antibody GSK3511294 in patients with asthma (2021) (5)
- ERS International Congress, Madrid, 2019: highlights from the Airway Diseases, Asthma and COPD Assembly (2020) (5)
- The efficacy of extrafine beclomethasone dipropionate–formoterol fumarate in COPD patients who are not “frequent exacerbators”: a post hoc analysis of the FORWARD study (2017) (5)
- Single inhaler triple therapy with extrafine beclomethasone, formoterol, and glycopyrronium for the treatment of chronic obstructive pulmonary disease (2018) (5)
- A randomized placebo and active controlled trial of AZD8871 a novel dual acting bronchodilator in COPD patients (2017) (4)
- Use of concomitant inhaled corticosteroids: pooled data from two phase III studies of aclidinium plus formoterol in COPD (2017) (4)
- Cyclic hydrostatic pressure and cotton particles stimulate synthesis by human lung macrophages of cytokines in vitro (2009) (4)
- Triple Therapy in Chronic Obstructive Pulmonary Disease. (2017) (4)
- Realising the potential of various inhaled airway challenge agents through improved delivery to the lungs. (2018) (4)
- Tiotropium + olodaterol fixed-dose combination shows clinically meaningful improvements in quality of life versus placebo (2015) (4)
- Evaluation of systemic absorption and bronchodilator effect of glycopyrronium bromide delivered by nebulizer or a dry powder inhaler in subjects with chronic obstructive pulmonary disease (2019) (4)
- Prognostic value of clinically important deterioration in COPD: IMPACT trial analysis (2021) (4)
- Predicting Pneumonia in Chronic Obstructive Pulmonary Disease. Have We Unraveled the Network of Risks? (2020) (4)
- The role of CRAC channel in asthma. (2015) (4)
- Comparison of the effect of beclometasone/formoterol in asthma patients after methacholine‐induced bronchoconstriction: A noninferiority study using metered dose vs. dry powder inhaler (2019) (4)
- Reduced antibacterial immunity in chronic obstructive pulmonary disease: a key role for lymphocytes? (2014) (4)
- RPL554, an inhaled PDE3/4 inhibitor, causes profound and sustained bronchodilation in healthy volunteers and COPD patients (2016) (4)
- The TRIFLOW study: a randomised, cross-over study evaluating the effects of extrafine beclometasone/formoterol/glycopyrronium on gas trapping in COPD (2020) (4)
- Inhaled Steroids and Active Smoking Drive Chronic Obstructive Pulmonary Disease Symptoms and Biomarkers to a Greater Degree Than Airflow Limitation (2017) (4)
- High- and low-dose allergen challenges in asthmatic patients using inhaled corticosteroids. (2015) (4)
- Double combination inhalers in COPD: How to get your head around this data (2018) (4)
- Type‐2 airway inflammation in mild asthma patients with high blood eosinophils and high fractional exhaled nitric oxide (2021) (4)
- Discordant diagnostic criteria for pneumonia in COPD trials: a review (2021) (4)
- Inhaled Phosphodiesterase Inhibitors for the Treatment of Chronic Obstructive Pulmonary Disease (2021) (3)
- Optimum treatment for chronic obstructive pulmonary disease exacerbation prevention. (2016) (3)
- One More Time: The Impact of Inhaled Corticosteroid Withdrawal on IMPACT (2020) (3)
- Effect of aclidinium bromide/formoterol fumarate fixed-dose combination (FDC) on night-time and early morning symptoms in COPD (2014) (3)
- Dysregulation of the CD163-Haptoglobin Axis in the Airways of COPD Patients (2021) (3)
- Effect of Age on the Efficacy and Safety of Once-Daily Single-Inhaler Triple Therapy Fluticasone Furoate/Umeclidinium/Vilanterol in Patients With Chronic Obstructive Pulmonary Disease: A Post Hoc Analysis of the IMPACT Trial. (2020) (3)
- Aclidinium bromide/formoterol fumarate as a treatment for COPD: an update (2021) (3)
- Intranasal GSK2245035, a Toll-like receptor 7 agonist, does not attenuate the allergen-induced asthmatic response in a randomized, double-blind, placebo-controlled experimental medicine study (2020) (3)
- Lipids in the lung: Respiratory inflammation in COPD (2012) (3)
- P254 NVA237 once daily improves exercise endurance in patients with COPD from the first dose: the GLOW3 trial (2011) (3)
- Different inhaled allergen challenge models give reproducible results. (2015) (3)
- Dose responses for topical efficacy and systemic activity, dose equivalence and relative therapeutic index for fluticasone furoate (FF), fluticasone propionate (FP) and budesonide (BUD) in asthmatic subjects (2019) (3)
- A single blood eosinophil count measurement is as good as two for prediction of ICS treatment response in the IMPACT trial (2021) (3)
- Alveolar macrophage size is increased in COPD patients compared to controls (2017) (3)
- Effects Of Low Dose Inhaled Theophylline (ADC4022) Co-administered With Budesonide On Inflammatory Markers And Lung Function In Patients With COPD (2010) (3)
- Global Initiative for Chronic Obstructive Lung Disease 2023 Report: GOLD Executive Summary (2023) (3)
- Extrafine triple therapy and asthma exacerbation seasonality: TRIMARAN and TRIGGER post-hoc analyses. (2021) (3)
- Late Breaking Abstract - RPL554, a first-in-class dual PDE3/4 inhibitor, causes significant bronchodilation and symptom relief; a Phase 2b COPD study (2018) (3)
- Effect of CHF5993 pMDI (extrafine Beclometasone Dipropionate:BDP,Formoterol Fumarate:FF,Glycopyrronium Bromide:GB) on Clinically Important Deteriorations (CID) in COPD: post-hoc analysis of TRINITY study (2017) (3)
- Usability and Robustness of the Wixela Inhub Dry Powder Inhaler (2020) (3)
- Efficacy and safety of single-inhaler extrafine triple therapy versus inhaled corticosteroid plus long-acting beta2 agonist in eastern Asian patients with COPD: the TRIVERSYTI randomised controlled trial (2021) (3)
- Efficacy and safety of aclidinium/formoterol fixed-dose combination in patients with moderate to severe airflow obstruction, stratified by severity (2015) (3)
- Late Breaking Abstract - Small Airways Dysfunction (SAD) correlates with relevant asthma outcomes: longitudinal results from the AssessmenT of smalL Airways involvemeNT In aSthma (ATLANTIS) Study (2020) (3)
- Reply to: ‘evaluating triple ICS/LABA/LAMA therapies for COPD patients: a network meta-analysis of ETHOS, KRONOS, IMPACT, and TRILOGY studies’ (2020) (3)
- One bronchodilator or two? Translating clinical trials into clinical practice (2020) (3)
- Reproducibility of nasal allergen challenge responses in adults with allergic rhinitis (2019) (3)
- Inhibition of p38 mitogen-activated protein kinase has no effect on macrophage phagocytosis of bacteria in patients with COPD (2013) (2)
- Efficacy of tiotropium/olodaterol compared with tiotropium in patients naive to LAMA, LABA and ICS: Pooled analysis of four clinical trials (2019) (2)
- COPD lungs show an attached stratified mucus layer resembling the protective colonic mucus (2017) (2)
- A phase 2 study of the inhaled pan-JAK inhibitor TD-0903 in severe COVID-19: Part 1 (2021) (2)
- Novel ventilation-perfusion ratio measurements in COPD using MRI (2011) (2)
- Characteristics of prominent response to triple therapy in patients with asthma uncontrolled on ICS/LABA: A stratified analysis of the TRIMARAN and TRIGGER studies (2019) (2)
- P256 Aclidinium bromide: a Phase IIb, dose-finding study (2011) (2)
- COPD exacerbation benefits relative to pneumonia risk with budesonide/glycopyrronium/formoterol metered dose inhaler: analyses from ETHOS (2020) (2)
- P271 Effect of extrafine single inhaler triple therapy on lung function and use of rescue medication: results from the trinity study (2017) (2)
- TLR Stimulation Induces Glucocorticoid Insensitive Production Of Functional Neutrophil Chemoattractant From COPD Alveolar Macrophages (2011) (2)
- Effects of cigarette smoke on TLR activation of COPD macrophages. (2014) (2)
- The Manchester Respiratory-related Sleep Symptoms scale for patients with COPD: development and validation (2018) (2)
- LATE-BREAKING ABSTRACT: The novel inhaled dual PDE3/4 inhibitor RPL554 produces significant additional improvements in lung function when administered on top of existing standard of care in COPD patients (2016) (2)
- Bronchial epithelial gene expression of NOX isoforms are related to important clinical characteristics in COPD (2016) (2)
- Stability of eosinophilic inflammation in COPD bronchial biopsies (2020) (2)
- Identifying small airway dysfunction in asthma in clinical practice (2020) (2)
- New insights into the optimal management of COPD: extracts from CHEST 2021 annual meeting (October 17–20, 2021) (2022) (2)
- Lung function improvements following inhaled indacaterol/glycopyrronium/mometasone furoate are independent of dosing time in asthma patients: a randomised trial (2020) (2)
- Researchneutrophils as a biomarker in COPD: findings from the ECLIPSE study (2010) (2)
- TD-8236, a lung-selective inhaled pan-JAK inhibitor, inhibits gene expression related to severe asthma and exhaled nitric oxide (FeNO), in 3-D airway epithelium liquid interface (ALI) cultures derived from asthmatic donors (2020) (2)
- The reproducibility of bolus allergen challenges; power calculations for clinical trials (2013) (2)
- Clinically important deterioration in patients with COPD using umeclidinium/vilanterol, tiotropium or placebo: Pooled data (2015) (2)
- CHF5993 pMDI (extrafine Beclometasone Dipropionate:BDP, Formoterol Fumarate:FF, Glycopyrronium Bromide:GB) reduces Clinically Important Deteriorations (CID) in COPD: post-hoc analysis of TRILOGY study (2017) (2)
- A randomised, double-blind, placebo-controlled study to evaluate the efficacy of oral azithromycin as a supplement to standard care for adult patients with acute exacerbations of asthma (the AZALEA trial) (2016) (2)
- Pharmacodynamic and pharmacokinetic results after repeated doses of AZD8871 in COPD patients (2018) (2)
- InforMing the PAthway of COPD Treatment Single-Inhaler Triple Therapy (Fluticasone Furoate/ Umeclidinium/ Vilanterol) Versus Fluticasone Furoate/Vilanterol and Umeclidinium /Vilanterol in Patients With COPD: Analysis of the Western Europe and North America Regions. (2020) (2)
- An 'Omics' Study to Investigate the Mechanisms Underlying Circadian Rhythm in Asthma (2018) (2)
- Risankizumab in severe asthma: A Phase IIa, placebo-controlled study (2020) (2)
- Predictive modeling of COPD exacerbation rates using baseline risk factors (2020) (2)
- Late Breaking Abstract - Small airways dysfunction predicts asthma control and exacerbations: Longitudinal Data from ATLANTIS Study (2021) (2)
- GS-5759, A Novel Bi-Functional Phosphodiesterase 4 Inhibitor And Long-Acting ²2-Adrenoceptor Agonist Inhibits Cytokine Production From COPD Alveolar Macrophages (2012) (2)
- A Randomised, Placebo Controlled Trial Of The Effect Of An Inhaled Syk Inhibitor On Allergen Induced Airways Responses In Mild Asthma (2012) (2)
- Exhaled Volatile Organic Compounds As Potential Biomarkers In Chronic Obstructive Pulmonary Disease (2010) (2)
- Assessment of bacterial exposure on phagocytic capability and surface marker expression of sputum macrophages and neutrophils in COPD patients (2021) (2)
- A sputum 6-gene signature predicts airway inflammation endotypes and exacerbation frequency in chronic obstructive pulmonary disease. (2022) (2)
- Effect of chronic mucus hypersecretion on treatment responses to inhaled therapies in patients with chronic obstructive pulmonary disease: Post hoc analysis of the IMPACT trial (2022) (2)
- Metabolomics Of Breath Volatile Organic Compounds For The Diagnosis And Inflammatory Phenotyping Of Adult Asthma (2010) (2)
- P299 Effects of symptom severity at baseline on lung-function and SGRQ responses in the otemto® studies (2016) (2)
- IL-33 in COPD: the hunt for responder subgroups. (2022) (2)
- Ventilation-perfusion mismatch in COPD with or without emphysema: Comparison of structural CT and functional OE-MRI (2011) (2)
- P255 ATTAIN: twice-daily aclidinium bromide in patients with moderate to severe chronic obstructive pulmonary disease (2011) (2)
- Global Initiative for Chronic Obstructive Lung Disease 2023 Report: GOLD Executive Summary (2023) (2)
- Eosinophilic versus non-eosinophilic COPD cannot be distinguished by lung function nor CT determined emphysema or airway remodelling (2016) (1)
- The Effect Of The Novel Phosphodiesterase-4 Inhibitor MEM 1414 On The Allergen-induced Responses In mild Asthma (2010) (1)
- Anti-inflammatory effects of the novel phosphodiesterase type 4 inhibitor CHF6001 on COPD alveolar macrophages and lung tissue (2014) (1)
- Prediction Of A COPD Exacerbation Phenotype Using Blood Transcriptomic Markers (2011) (1)
- Impact of grouping patients by 2017 GOLD strategy assessment criteria: a post hoc analysis of the TONADO and OTEMTO trials (2017) (1)
- Characterisation of the bronchial epithelium in COPD frequent exacerbators (2019) (1)
- Inhaled triple therapy in chronic obstructive pulmonary disease – Authors' reply (2018) (1)
- Dose-Ranging Study To Assess The Safety And Pharmacokinetic Profile Of Nebulized Glycopyrrolate (EP-101) Using High Efficiency Nebulizer In COPD Patients (2012) (1)
- Role of regulatory T-cells in COPD (2010) (1)
- FEV1 recovery following methacholine challenge in asthma: Variability and comparison of methods. (2019) (1)
- Physiological modelling of dynamic contrast-enhanced MRI in COPD (2012) (1)
- The dose response of inhaled LPS challenge in healthy subjects (2018) (1)
- The benefits of combined treatment with corticosteroids and long-acting beta agonists (2006) (1)
- Additive anti-inflammatory effect of glucocorticoids and PDE4 inhibitors on COPD CD8 cells (2014) (1)
- Lung bioavailability of beclometasone dipropionate and formoterol fumarate fixed dose combination administered using a pMDI or a novel DPI: NEXThaler® (2012) (1)
- Clinically important deteriorations in COPD as a measure of response to dual and mono bronchodilator therapy with and without inhaled corticosteroids (2015) (1)
- RISK OF DEATH AND COPD HOSPITALIZATION WITH FLUTICASONE FUROATE-CONTAINING THERAPY: POST HOC SUBGROUP ANALYSIS FROM THE SUMMIT TRIAL IN PATIENTS WITH COPD AND A HISTORY OF EXACERBATION (2020) (1)
- TREATMENT EFFECTS OF FF/UMEC/VI VS FF/VI AND UMEC/VI IN REVERSIBLE AND NONREVERSIBLE COPD PATIENTS: ANALYSES OF THE IMPACT STUDY (2018) (1)
- COPD exacerbation rates by month in the ETHOS trial with budesonide/glycopyrronium/formoterol metered dose inhaler (BGF MDI) at two ICS dose levels (2020) (1)
- Evaluation of individual activity descriptors of the MRC dyspnoea scale: Do they add up? (2015) (1)
- Extrafine beclometasone dipropionate, formoterol fumarate, glycopyrronium (BDP/FF/G) and exacerbation recurrence: post-hoc analysis of the TRIBUTE study. (2018) (1)
- Predicting Pneumonia in COPD: Have We Unraveled the Network of Risks? (2020) (1)
- FORWARD: A study of extrafine beclomethasone/formoterol compared with formoterol alone in patients with severe COPD and a history of exacerbations (2013) (1)
- Effects Of Oral And Inhaled P38 Inhibitors On Sputum Inflammatory Markers Following Whole Lung Lipopolysaccharide (LPS) Challenge In Healthy Subjects (2012) (1)
- Increased expression of phosphodiesterase 4 (PDE4) A, B and D in alveolar macrophages from chronic obstructive pulmonary disease (COPD) patients (2011) (1)
- CRAC channel inhibition produces greater anti-inflammatory effects than glucocorticoids in COPD CD8 cells (2015) (1)
- Macrophages, corticosteroids and COPD: what do we know? (2016) (1)
- Relationship between blood eosinophil count and bronchial epithelial gene expression in COPD versus Asthma (2018) (1)
- The possible association between systemic inflammatory biomarkers and depression and fatigue in moderate clinically stable COPD (2010) (1)
- Reproducibility of COPD blood eosinophil counts (2018) (1)
- The Perception of Physicians on Gender-Specific Differences in the Diagnosis of COPD: Results from a Questionnaire-Based Survey (2021) (1)
- Effect of triple therapy with extra-fine BDP/FF/GB pMDI vs non-triple maintenance therapies on severe COPD exacerbations. A pooled analysis of the TRILOGY, TRINITY and TRIBUTE studies (2020) (1)
- INHALEd nebulised unfractionated HEParin for the treatment of hospitalised patients with COVID-19 (INHALE-HEP): Protocol and Statistical Analysis Plan for an investigator-initiated international meta-trial of randomised studies (2020) (1)
- Correction: Loss of Glucocorticoid Receptor Expression by DNA Methylation Prevents Glucocorticoid Induced Apoptosis in Human Small Cell Lung Cancer Cells (2013) (1)
- Tiotropium; more knowledge leads to more questions. (2008) (1)
- Letter to editor – a response to: ‘efficacy and safety of triple combination therapy for treating chronic obstructive pulmonary disease: an expert review’ (2021) (1)
- Misinterpretation of time-to-first event curves can lead to inappropriate treatment (2019) (1)
- Overcoming Therapeutic Inertia to Reduce the Risk of COPD Exacerbations: Four Action Points for Healthcare Professionals (2021) (1)
- Patterns of symptom change measured using the EXACT diary associated with prescription of corticosteroids or antibiotics in COPD exacerbations (2015) (1)
- Normalization of Airflow Obstruction with Extra Fine Beclomethasone Dipropionate, Formoterol Fumarate, and Glycopyrronium Bromide (BDP/FF/GB) pMDI: A Post-Hoc Analysis of the TRIMARAN and TRIGGER Studies (2021) (1)
- Comparative Real-World Effectiveness of Triple Therapy Versus Dual Bronchodilation on Lung Function Decline in Frequently Exacerbating Patients with COPD (2019) (1)
- Safety, Pharmacokinetics and Immunogenicity of the Anti-Interleukin-33 Antibody, Tozorakimab: Results of a Phase 1 Study in Healthy Adults and Patients with Chronic Obstructive Pulmonary Disease (2022) (1)
- Abstracts from the 3rd International Severe Asthma Forum (ISAF) (2017) (1)
- Prevalence of airflow obstruction in patients attending a rapid access chest pain clinic. (2009) (1)
- FF/UMEC/VI versus FF/VI and UMEC/VI in the ELLIPTA device in patients with COPD: Subgroup analyses from the IMPACT trial (2018) (1)
- Effect of indacaterol/glycopyrronium on ventilation and perfusion in COPD: a randomized trial (2022) (1)
- Efficacy of aclidinium/formoterol: pooled post hoc analysis of patients naïve to COPD maintenance therapy (2017) (1)
- P273 Association of incident pneumonia and exacerbations with extrafine triple therapy in one single inhaler in copd patients: a post-hoc analysis from trilogy and trinity studies (2017) (1)
- Development of a tool to detect small airways dysfunction in asthma clinical practice (2022) (1)
- Relationship between prior inhaled corticosteroid use and benefits ofbudesonide/glycopyrronium/formoterol fumarate dihydrate on exacerbations, symptoms, health-related quality of life, and lung function in patients with chronic obstructive pulmonary disease: Analyses from the ETHOS study. (2022) (1)
- Impact of inhaled fluticasone propionate/salmeterol on health-related quality of life in asthma: A network meta-analysis. (2022) (1)
- Phase 1 and 2 Randomized Clinical Studies Determine Lack of Efficacy for Anti-IL-17C Antibody MOR106 in Moderate–Severe Atopic Dermatitis (2022) (1)
- Rhinovirus Challenge in Asthmatics and Healthy Volunteers to Evaluate the Safety and Appropriate Dose of a GMP Human Rhinovirus 16 Preparation for Challenge Studies in Mild-Moderate Asthmatics taking ICS (2018) (1)
- Lung Function Normalisation with Indacaterol Acetate/Glycopyrronium Bromide/Mometasone Furoate in Patients with Asthma (2021) (1)
- Inhaled corticosteroid (ICS) induced metabolome changes in asthmatics (2020) (1)
- Relationship between prior triple therapy use and benefits of budesonide/glycopyrronium/formoterol on exacerbation risk: analysis from ETHOS (2021) (0)
- Benefits of Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate on COPD Exacerbations, Lung Function, Symptoms, and Quality of Life Across Blood Eosinophil Ranges: A Post-Hoc Analysis of Data from ETHOS (2022) (0)
- High degree of polyclonality hinders somatic mutation calling in lung brush samples of COPD cases and controls (2019) (0)
- Reply to: “Intraclass Difference in Pneumonia Risk with Fluticasone and Budesonide in COPD: A Systematic Review of Evidence from Direct-Comparison Studies” [Letter] (2021) (0)
- ADEPT, airway disease endotyping for personalized treatment: Interim analysis of asthma patients (2013) (0)
- Lung function with aclidinium/formoterol fixed-dose combination: Pooled analysis of two phase III studies in COPD (2015) (0)
- Physicians’ perceptions on gender differences in the diagnosis and management of COPD (2018) (0)
- Reply to Wang and Lai: The Role of Eosinophils during the Withdrawal of Inhaled Corticosteroids in Chronic Obstructive Pulmonary Disease (2021) (0)
- Changes in FEV1 over 8 years in COPD (2016) (0)
- COPD_A_269287 2739..2750 (2020) (0)
- Correction to: Measuring disease activity in COPD: is clinically important deterioration the answer? (2021) (0)
- Markers of eosinophilic inflammation are associated with response to the DP2 antagonist GB001 in patients with mild atopic asthma (2019) (0)
- Effect of the interleukin-13 neutralising monoclonal antibody , tralokinumab , on eosinophilic airway inflammation in uncontrolled moderate to severe asthma ( MESOS – a randomised placebo-controlled phase 2 clinical trial ) (2018) (0)
- Assessment of the phagocytic capability of sputum macrophages and neutrophils in COPD patients (2019) (0)
- Effect of CHF6001, a novel inhaled phosphodiesterase-4 inhibitor (PDE4i) on markers of inflammation in COPD patients (2019) (0)
- TREATMENT EFFECTS OF FF/UMEC/VI VS FF/VI AND UMEC/VI IN COPD PATIENTS BY AIRFLOW LIMITATION SEVERITY: POST-HOC ANALYSES OF THE IMPACT STUDY (2018) (0)
- Prevalence of metabolic syndrome among patients with chronic obstructive pulmonary disease: A systematic review and meta-analysis (2015) (0)
- Proteobacteria phylum association with airway- and emphysema-dominant COPD phenotypes defined by computed tomography (2021) (0)
- Predictors of health status in COPD patients (2008) (0)
- Mucosal explant induced migration of T-cells from severe asthmatics is inhibited by CCR4 antagonism (2012) (0)
- Blood eosinophils and treatment response with triple and dual combination therapy in COPD: analysis of the IMPACT trial (2019) (0)
- Stability of sputum and blood eosinophil levels in COPD (2020) (0)
- BLOOD EOSINOPHILS AS A PREDICTIVE MARKER OF EXACERBATION RISK IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE: RESULTS FROM A POOLED ANALYSIS OF 22,125 PATIENTS (2019) (0)
- artery thrombosis Coronary artery thrombosis Myocardial infarction Brain stem infarction Embolic cerebral infarction Papillary muscle infarction Brain stem stroke Embolic stroke Post procedural myocardial Brain stem thrombosis Hemorrhagic cerebral infarction Post procedural stroke Carotid arterial e (2011) (0)
- Efficacy and safety of abediterol, a long-acting β2-adrenergic agonist (LABA); three phase II trials in asthma (2014) (0)
- Extrafine glycopyrronium bromide (GB) in addition to extrafine beclomethasone dipropionate/formoterol fumarate (BDP/FF) in uncontrolled asthmatic patients (2018) (0)
- Dynamic changes in quadriceps strength and 6 minute walk distance during COPD exacerbations in the COPDMAP consortium (2014) (0)
- New Insights Into COPD Exacerbations And Patient/physician Behaviour Detected With Daily Records Of Exact-Pro And Blackberry (2011) (0)
- Clinical Characteristics Of The COPD 'Persistent Sputum Producer' (2012) (0)
- Identification of Ki67+ ‘monocytic’ cells within the lungs (2016) (0)
- The modulatory effects of Nrf2 activators in a pulmonary arterial hypertension model (2020) (0)
- Characteristics and longitudinal progression of COPD GOLD B (2016) (0)
- Late Breaking Abstract - Blood eosinophil count and exacerbation history in COPD: pooled analysis of 24,103 patients (2019) (0)
- Explorer Genetics of sputum gene expression in chronic obstructive pulmonary disease (2017) (0)
- Bronchodilator effect of high strength extrafine BDP/formoterol delivered via NEXThaler® in asthmatics (2015) (0)
- Alveolar macrophages activate STAT3 in epithelial cells via gp130 dependant steroid insensitive mechanism (2013) (0)
- Lung Clearance Index (LCI) measurements are reproducible and associated with airway physiological changes in steroid naive asthmatic (SNA) adults (2017) (0)
- University of Southern Denmark Effect of tralokinumab, an interleukin-13 neutralising monoclonal antibody, on eosinophilic airway inflammation in uncontrolled moderate-to-severe asthma (MESOS) a multicentre, double-blind, randomised, placebo-controlled phase 2 trial (2018) (0)
- ENSIFENTRINE, A NOVEL DUAL PHOSPHODIESTERASE (PDE) 3 AND 4 INHIBITOR, PROVIDES EFFECTIVE BRONCHODILATION WHEN ADMINISTERED BY METERED DOSE INHALER IN PATIENTS WITH COPD (2020) (0)
- Anti-inflammatory effect of a novel inhaled dual PDE3/4 inhibitor RPL554 in man, a unique "first-in-class" drug for the treatment of COPD & asthma (2013) (0)
- The Reproducibility Of LPS Challenge In Healthy Smokers (2012) (0)
- Overcoming The Steroid Insensitivity Of Leukotriene B4 (LTB4) Production In Human Alveolar Macrophages: Pharmacological Inhibition Of 5-Lipoxygeanase And FLAP Enzymes (2011) (0)
- Aclidinium bromide for the treatment of chronic obstructive pulmonary disease (2012) (0)
- EFFECT OF AGE ON EFFICACY AND SAFETY OF ONCE-DAILY SINGLE-INHALER TRIPLE THERAPY FLUTICASONE FUROATE/UMECLIDINIUM/VILANTEROL IN PATIENTS WITH COPD: A POST-HOC ANALYSIS OF THE IMPACT TRIAL (2019) (0)
- Differential bronchial epithelial gene expression in COPD versus controls (2016) (0)
- F1000Prime recommendation of A comprehensive care management program to prevent chronic obstructive pulmonary disease hospitalizations: a randomized, controlled trial. (2012) (0)
- Evaluation of the Individual Activity Descriptors of the mMRC Breathlessness Scale: A Mixed Method Study (2022) (0)
- A Dose-Ranging Study (TERRANOVA) of Benralizumab for Moderate to Severe Chronic Obstructive Pulmonary Disease (2019) (0)
- Biological treatments in airway diseases (2016) (0)
- Benefits of tiotropium/olodaterol compared with tiotropium in patients with COPD receiving only LAMA at baseline: pooled analysis of 4 clinical trials (2019) (0)
- Inhaled Lipopolysaccharide (LPS) In Patients With COPD (2012) (0)
- Development of the Manchester early morning symptoms index in COPD (2014) (0)
- The effects of Nrf2 activators and oxidative stress on COPD alveolar macrophages (2020) (0)
- Increased MUC5B and carbonic anhydrase IX expression in the bronchial epithelium of COPD persistent sputum producers (2014) (0)
- INCREASED IL-18 RECEPTOR EXPRESSION IN COPD LUNG MACROPHAGES (2010) (0)
- Reliever effect of extrafine BDP/F DPI in asthmatic patients after methacholine challenge (2018) (0)
- P276 Cardiovascular safety of extrafine single inhaler triple combination of beclometasone dipropionate, formoterol fumarate, and glycopyrronium bromide in copd: results of safety analysis from the trilogy and trinity studies (2017) (0)
- Association between COPD bronchial brush microbiome-determined ?Proteobacteria:Firmicutes (G:F) ratio and GOLD grade and symptoms (2019) (0)
- COPD_A_217710 2835..2848 (2019) (0)
- Which bronchodilator in COPD? (2007) (0)
- LATE-BREAKING ABSTRACT: Safety, pharmacokinetic and pharmacodynamic profile of RV1162, a narrow spectrum kinase inhibitor, in healthy subjects and COPD patients (2015) (0)
- Bronchiectasis, the Latest Eosinophilic Airway Disease: What about the Microbiome? (2022) (0)
- The bronchial expression of vanin in moderate to severe asthma (2019) (0)
- Corticosteroid Insensitivity Of Mixed Sputum Cells (2011) (0)
- Cardiovascular safety of extrafine beclomethasone/formoterol (BDP/FF) delivered via a novel dry powder inhaler (NEXThaler®) in COPD patients (2015) (0)
- Lung function improvements with twice-daily aclidinium/formoterol fixed-dose combination in two 24-week studies in patients with COPD (2014) (0)
- Reproducibility of the cytokine response following nasal allergen challenge (2013) (0)
- ENSIFENTRINE, A DUAL PDE 3 AND 4 INHIBITOR, PROVIDES EFFECTIVE BRONCHODILATION IN PATIENTS WITH COPD WHEN ADMINISTERED TWICE DAILY OVER 7 DAYS VIA PMDI (2021) (0)
- Increased IL-6 Within BAL Fluid Of COPD Patients (2011) (0)
- COPD_A_329316 3009..3016 (2021) (0)
- COPD_A_263025 2199..2206 (2020) (0)
- A Comparison of the Real-Life Clinical Effectiveness of the Leading Licensed ICS/LABA Combination Inhalers in the Treatment for COPD (2020) (0)
- Late Breaking Abstract - Pneumonia risk in COPD patients initiating extrafine Fixed Dose Combination (FDC) with beclometasone dipropionate (ef-FDC-BDP) versus long-acting bronchodilators (LABD) (2021) (0)
- LCI as an endpoint in COPD: Comparison with healthy controls, using SF6 and nitrogen washout (2014) (0)
- Late Breaking Abstract - Reduction of COPD exacerbations with extrafine single inhaler triple therapy: post-hoc analysis by exacerbation treatment of the TRIBUTE study (2018) (0)
- BENEFIT–RISK PROFILES OF FLUTICASONE FUROATE/UMECLIDINIUM/VILANTEROL (FF/UMEC/VI) VS UMEC/VI IN PATIENTS WITH COPD: A MARKOV MODEL (2020) (0)
- Prevotella genera abundance in bronchial brush samples differentiates COPD from health and is associated with gene expression (2019) (0)
- LATE-BREAKING ABSTRACT: Single-dose safety, tolerability, PD & PK of AZD8999, a bi-functional muscarinic antagonist/β2-agonist (MABA), in patients with COPD (2016) (0)
- Targeting PI3Kδ or JAK in T-cells from COPD and severe asthma subjects reduces corticosteroid insensitive inflammatory responses (2013) (0)
- WITHDRAWN: The modulatory effects of the PDE4 inhibitors CHF6001 and roflumilast in alveolar macrophages and lung tissue from COPD patients (2019) (0)
- Corticosteroid Insensitivity In CD8 Cells From COPD Patients Is Overcome By Targeting NFAT (2011) (0)
- Blood eosinophils in COPD: relationship with CLCA1 and mucus production (2018) (0)
- Late Breaking Abstract - Identification of patients with COPD who benefit from benralizumab (2019) (0)
- Mechanisms of impaired anti-bacterial Th1 responses in patients with chronic obstructive pulmonary disease (2018) (0)
- The effect of muscle wasting on exercise capacity and depression in patients with chronic obstructive pulmonary disease (2007) (0)
- Additional file 5: of The effects of corticosteroids on COPD lung macrophages: a pooled analysis (2015) (0)
- The pharmacokinetics, pharmacodynamics and tolerability of PUR0200, a novel tiotropium formulation, in chronic obstructive pulmonary disease: PUR0200, a tiotropium formulation, in COPD (2018) (0)
- Effect of corticosteroids on lymphocytes from severe asthma patients (2012) (0)
- DuoResp Spiromax adherence, satisfaction and ease of use: findings from a multi-country observational study in patients with asthma and COPD (SPRINT) (2018) (0)
- COPD_A_263745 3093..3103 (2020) (0)
- Changes In The Small Airway Microvasculature Of Sputum Producing COPD Patients (2012) (0)
- Impaired monocyte chemotaxis in COPD (2015) (0)
- Noninvasive Ventilation as a Weaning Tool (2010) (0)
- Risk factors for all-cause mortality in patients with COPD: results from the ETHOS trial (2021) (0)
- The effect of GSK2190915, a 5-lipoxygenase activating protein inhibitor, on the allergen induced asthmatic response (2011) (0)
- Identification of mechanism-specific biomarkers to guide development of the lung-selective inhaled pan-JAK inhibitor TD-8236 (2020) (0)
- Depression and exercise capacity limitation in COPD (2008) (0)
- LATE-BREAKING ABSTRACT: TRILOGY: a phase III study to evaluate the efficacy and safety of an extrafine triple combination of beclometasone dipropionate (BDP), formoterol fumarate (FF), and glycopyrronium bromide (GB) pMDI (CHF5993) in COPD patients (2016) (0)
- Reproducibility Of Bolus Allergen Challenge (2011) (0)
- Leukotriene B4 Levels In Induced Sputum From Differing Severities Of Asthma (2010) (0)
- Air Pollution and COPD: GOLD 2023 committee REport. (2023) (0)
- Reverbα is a novel regulator of COPD macrophage inflammation and glucocorticoid resistance (2011) (0)
- Synergistic effects of p38 MAPK inhibition with a corticosteroid in alveolar macrophages from corticosteroid insensitive asthma patients (2013) (0)
- New Frontiers in Chronic Obstructive Pulmonary Disease: Where Are We Heading? (2022) (0)
- Small Airway Dysfunction Predicts Asthma Control and Exacerbations : Longitudinal Data from the Assessment of Small Airways Involvement in Asthma (ATLANTIS) Study (2021) (0)
- IFN? Synergistically Enhances LPS Signalling By Corticosteroid Resistant STAT1 Activation In COPD Alveolar Macrophages (2011) (0)
- Airway inflammation in asthma: multiple roles for thymic stromal lymphopoietin. (2012) (0)
- The Role Of Liver X Receptor In Chronic Obstructive Lung Disease (2011) (0)
- Extrafine Beclometasone Dipropionate/Formoterol Fumarate vs Double Bronchodilation Therapy in Patients with COPD: A Historical Real-World Non-Inferiority Study (2020) (0)
- The TRIFLOW study; A randomised, cross-over study evaluating the effects of inhaled beclometasone/formoterol/glycopyrronium (BDP/F/G) on hyperinflation in COPD (2020) (0)
- Alveolar presence of red blood cells correlates with alveolar macrophage iron levels in COPD (2020) (0)
- TIME-DEPENDENT RISK OF CARDIOVASCULAR EVENTS FOLLOWING AN EXACERBATION IN PATIENTS WITH COPD: POST HOC ANALYSIS FROM THE IMPACT TRIALl (2020) (0)
- Expiratory flow limitation in a cohort of highly symptomatic COPD patients (2022) (0)
- Building Hope by Restoring Breathing in Airways Diseases (2019) (0)
- Effect of triple therapy with extra-fine BDP/FF/GB pMDI during seasonal peaks of asthma exacerbations. A post-hoc analysis of the TRIMARAN and TRIGGER studies (2020) (0)
- LPS Challenge Leads To Increased Neutrophil Chemotaxis In Healthy Volunteers (2011) (0)
- study the estrogen (ER) and progesterone (PR) receptor in case of primary and metastatic breast cancer (2022) (0)
- 17-BMP Potently Suppresses TNFα Production from COPD Alveolar Macrophages. (2009) (0)
- UNIQUE DUAL PHOSPHODIESTERASE 3/4 INHIBITOR, ENSIFENTRINE, SIGNIFICANTLY IMPROVES COPD SYMPTOMS INCLUDING DYSPNEA (2019) (0)
- Inhaled glucocorticoid-induced metabolome changes in asthma (2022) (0)
- Enhanced IL-6 and CCL3 activity in COPD (2012) (0)
- LATE-BREAKING ABSTRACT: A Phase 1b study of PUR0200, a novel tiotropium formulation, in COPD patients (2015) (0)
- Adding budesonide to formoterol reduces risk of clinically important deteriorations (CID) in moderate to very severe COPD (2018) (0)
- Journal Pre-proof Impact of inhaled fluticasone propionate/salmeterol on health-related quality of life in asthma: A network meta-analysis (2022) (0)
- Dupilumab Efficacy in Patients with Uncontrolled, Moderate-to-Severe Asthma with Elevated Type 2 Biomarkers and Fixed Airflow Obstruction (2022) (0)
- Do ICS/LABA fixed combinations provide superior asthma control compared to separate inhalers? (2010) (0)
- Reply to Pouwels et al.: Confounding Factors Affecting sRAGE as a Biomarker for Chronic Obstructive Pulmonary Disease (2019) (0)
- Reply to: The Role of Eosinophil During the Withdrawal of Inhaled Corticosteroid in COPD. (2020) (0)
- Late Breaking Abstract - Increased type 2 inflammation in patients with asthma post rhinovirus infection (2018) (0)
- The effect of different tools in assessing the prevalence of depression in COPD patients (2008) (0)
- P298 Tiotropium/olodaterol therapy provides symptomatic benefits irrespective of prior maintenance treatment: post hoc analyses of the otemto® studies (2016) (0)
- P219 Evaluation of individual activity descriptors of the mrc dyspnoea scale: do they add up? (2016) (0)
- Analysis of Immunoglobulin A and M gene expression and plasma cells in bronchial tissue from COPD patients with high blood eosinophil counts (2018) (0)
- Synergistic Effects Of P38 Mitogen-Activated Protein Kinase (MAPK) Inhibition With A Corticosteroid In Alveolar Macrophages From Chronic Obstructive Pulmonary Disease (COPD) Patients (2011) (0)
- Impact of fatigue in patients with moderate clinically stable COPD using a novel COPD-specific fatigue scale (2009) (0)
- Mucins in COPD MUC 5 B is the major mucin in the gel-phase of sputum in chronic obstructive pulmonary disease (2008) (0)
- Variability Due to the Time of Reading (2017) (0)
- P274 Comparison of the initiation of copd treatment with licensed fdc ics/laba treatments in terms of disease control and cost effectiveness (2017) (0)
- Inhaled nebulised unfractionated heparin (UFH) for the treatment of hospitalised patients with COVID-19: A randomised controlled pilot study (2023) (0)
- Normalisation of airflow limitation in asthma: Post‐hoc analyses of TRIMARAN and TRIGGER (2022) (0)
- P299 Effects of symptom severity at baseline on lung-function and sgrq responses in the otemto® studies (2016) (0)
- Reply to: Confounding Factors Affecting sRAGE as Biomarker for COPD. (2019) (0)
- Predictors of Comparative Real-World Effectiveness of Triple Therapy Versus Dual Bronchodilation in Frequently Exacerbating Patients with COPD (2019) (0)
- THE DEVELOPMENT AND PRELIMINARY VALIDATION OF THE MANCHESTER SLEEP SYMPTOMS INDEX (MSSI) FOR PEOPLE WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD). (2014) (0)
- Inhaled LPS challenge in healthy subjects: a dose escalation study (2018) (0)
- The Changing Asthma Management Landscape and Need for Appropriate SABA Prescription (2023) (0)
- Development of the Manchester sleep symptoms index in COPD (2014) (0)
- Correction to: New Versus Old: The Impact of Changing Patterns of Inhaled Corticosteroid Prescribing and Dosing Regimens in Asthma Management (2022) (0)
- Cigarette smoke upregulates IL-8/CXCL8 expression by augmenting mRNA stability via p38 MAPK/MK2 signalling in normal human pulmonary cells (2012) (0)
- LPS Challenge In Healthy Smokers As A Model Of COPD (2011) (0)
- S60 Efficacy and safety of aclidinium/formoterol fixed-dose combination in patients with COPD, stratified by ICS use (2015) (0)
- DEMOGRAPHIC AND CLINICAL CHARACTERISTICS OF PATIENTS EXPERIENCING ON-TREATMENT EXACERBATIONS, ON-TREATMENT DEATH, OR PREMATURE STUDY TREATMENT WITHDRAWAL: THE IMPACT TRIAL (2020) (0)
- Benefits of tiotropium/olodaterol compared with tiotropium in patients receiving COPD LAMA at baseline: pooled analysis of 4 clinical trials (2020) (0)
- The relationship between blood eosinophils and bacterial load in COPD patients (2016) (0)
- TUESDAY, SEPTEMBER 27TH 2011 407. Immunology and cell biology of asthma and COPD (2011) (0)
- Effects of aclidinium bromide/formoterol fumarate fixed-dose combination on health status in COPD (2014) (0)
- The Circadian Biology of Asthma (2017) (0)
- The Development and Preliminary Validation of the Manchester Early Morning Symptoms Index (Memsi) for People With Chronic Obstructive Pulmonary Disease (Copd). (2014) (0)
- Late Breaking Abstract - Analysis of the InforMing the PAthway of COPD Treatment (IMPACT) study in the subgroup of patients taking triple therapy at screening (2018) (0)
- Trials in asthma : asthma exacerbations and severe asthma P 1782 Use of steroid receptor related STIP 1 gene analysis as an asthma marker (2012) (0)
- Mortality Risk and Serious Cardiopulmonary Events in Moderate-to-Severe COPD: Post Hoc Analysis of the IMPACT Trial. (2022) (0)
- Effect Of Corticosteroids On Lymphocytes From Mild Asthmatics (2011) (0)
- A New Approach To Ventilation-perfusion Mapping – Oxygen-enhanced Magnetic Resonance Imaging In Chronic Obstructive Pulmonary Disease (2010) (0)
- Role of T Regulatory Cells in the Pathogenesis of Asthma: Response (2010) (0)
- P55 Benefits of tiotropium/olodaterol on symptoms and health-related quality of life in patients with moderate to severe COPD with chronic bronchitis and/or emphysema (2016) (0)
- The effect of in vitro culture methods on corticosteroid sensitivity in COPD alveolar macrophages (2013) (0)
- Methacholine challenges: comparison of different tidal breathing challenge methods (2020) (0)
- INHALEd nebulised unfractionated HEParin for the treatment of hospitalised patients with COVID-19 (INHALE-HEP): Protocol for an investigator-initiated international meta-trial of randomised studies (2020) (0)
- Variability In Lung Function In Subjects Receiving Maintenance Therapy (2011) (0)
- Cigarette Smoke Elicits IL-8 Release in Pulmonary Cells through the ERK1/2 Pathway Activated by α,β-Unsaturated Aldehydes. (2009) (0)
- TLR2 and TLR4 induced tolerance in alveolar macrophages; differential effect on TNFα and IL-8 release (2012) (0)
- EvA consortium: bronchial brush bacterial load is associated with airway remodelling in mild-to-moderate COPD (2017) (0)
- Integration Of Gwas, eQTL, And Encode Data Identify Regulatory Variants And Cell Types Contributing To Patterns Of Radiographic Emphysema (2014) (0)
- Evaluating dynamic oxygen-enhanced MRI biomarkers of lung function: Sensitivity to conventional COPD treatment (2013) (0)
- Genetics Of Sputum Gene Expression Supports Two Distinct COPD Susceptibility Genes On Chromosome 15q25 (2011) (0)
- Effect Of Inhaled LPS Challenge On Corticosteroid Insensitivity In Healthy Smokers (2012) (0)
- Repeat Measurements of Complement proteins C3a and C5a in COPD patients (2017) (0)
- The effect of systemic inflammation on COPD severity and exercise capacity limitation in moderate clinically stable COPD (2010) (0)
- EFFECT OF EXTRA-FINE TRIPLE THERAPY WITH BECOMETHASONE DIPROPIONATE/FORMOTEROL FUMARATE/GLYCOPYRRONIUM BROMIDE (BDP/FF/GB) PRESSURIZED METERED DOSE INHALER (PMDI) ON EXACERBATIONS IN EAST ASIAN PATIENTS WITH COPD: THE TRIVERSYTI STUDY (2020) (0)
- Oral and inhaled p38 MAPK inhibitors: effects on inhaled LPS challenge in healthy subjects (2015) (0)
- One Bronchodilator or Two (2018) (0)
- Reduction in clinically important deterioration in COPD with aclidinium/formoterol (2016) (0)
- Over-reading of FRC using N2MBW compared to plethysmography and SF6MBW in COPD (2016) (0)
- Rev Erb Alpha: A Novel Anti-inflammatory Target, Is Responsible For The Circadian Secretion Of IL-6 (2010) (0)
- COPD bronchial brush microbiome association with lung function and bronchial gene expression (2020) (0)
- Validation of sputum supernatant biomarker assays in stable and exacerbating COPD subjects (2019) (0)
- Additional file 4: of The effects of corticosteroids on COPD lung macrophages: a pooled analysis (2015) (0)
- Efficacy and safety of four doses of CHF6001, a novel inhaled phosphodiesterase-4 inhibitor (PDE4i), in patients with moderate-to-severe COPD (2019) (0)
- Expression Of SER203, SER211 And SER226 Glucocorticoid Receptor Phosphorylation Sites In Human Alveolar Macrophages From COPD Lungs (2011) (0)
- Microarray Analysis Of COPD Pulmonary CD8 Cells (2012) (0)
- Reverb± Regulates The Macrophage's Temporal Inflammatory Response (2012) (0)
- Neutrophilic inflammation in sputum does not define a clinical distinct asthma phenotype in ATLANTIS (2021) (0)
- Repeatability Of Leukotriene B4 (LTB4) In PBS Sputum Supernatant Of Asthma Non-Smokers (2011) (0)
- The effect of GSK2190915, a 5-lipoxygenase activating protein inhibitor, on the early asthmatic response to inhaled allergen (2011) (0)
- COPD Phenotype Description Using Principal Components Analysis. (2009) (0)
- Asthma control and COPD symptom burden: results from a multi-country observational study (SPRINT) in patients using fixed dose combination (FDC) inhalers (2018) (0)
- Anti-inflammatory effects of the novel phosphodiesterase type 4 inhibitor CHF6001 on bronchoalveolar lavage lymphocytes from asthma patients (2017) (0)
- Increased P38 Mitogen Activated Protein Kinase In Chronic Obstructive Pulmonary Disease Lungs (2011) (0)
- COPD: The end of the beginning (2006) (0)
- Precision medicine in COPD, blood eosinophils and the GOLD 2019 (2020) (0)
- Multiple flow rate modelling of nitric oxide in COPD – methodological concerns (2006) (0)
- The reproducibility of bolus allergen challenges; power calculations for clinical trials (2012) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Dave Singh?
Dave Singh is affiliated with the following schools:
